The Hedgehog's tale: developing strategies for targeting cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Link
http://www.nature.com/articles/nrc3079.pdf
Reference133 articles.
1. Strizzi, L. et al. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res. 69, 7131–7134 (2009).
2. Yauch, R. L. et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326, 572–574 (2009). This study shows that an activating mutation in SMO confers resistance to GDC-0449 in advanced medulloblastoma, thus validating SMO as a clinical target.
3. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl. J. Med. 361, 1164–1172 (2009). The first report of clinical results showing responses in patients with advanced BCC to a SMO inhibitor.
4. Rudin, C. M. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. New Engl. J. Med. 361, 1173–1178 (2009). Describes the dramatic but transient response of a metastatic medulloblastoma to SMO inhibition.
5. Low, J. A. & de Sauvage, F. J. Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol. 28, 5321–5326 (2010).
Cited by 354 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth;Communications Biology;2024-05-17
2. Progesterone in frozen embryo transfer cycles: assays, circulating concentrations, metabolites, and molecular action;F&S Reports;2024-05
3. Human umbilical cord mesenchymal stem cell‐derived exosomes ameliorate renal fibrosis in diabetic nephropathy by targeting Hedgehog/SMO signaling;The FASEB Journal;2024-04-04
4. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma;Cancer Treatment and Research Communications;2024
5. Potential application of nanotechnology in the treatment and overcoming of pancreatic cancer resistance;Recent Advances in Nanocarriers for Pancreatic Cancer Therapy;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3